Modulation of ion channels in clinical psychopharmacology: adults and younger people

References

• Craddock N, Jones L, Jones IR et al. Strong enetic evidence for a selective influence of GABAA receptors on a component of the bipolar disorder phenotype. Mol. Psychiatry15(2), 146–153 (2010).
   PubMed Web of Science ®Google Scholar
• Green EK, Grozeva D, Jones I et al. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol. Psychiatry DOI: 10.1038/mp.2009.49 (2009) (Epub ahead of print).
   Google Scholar
• Bianchi MT, Pathmanathan J, Cash SS. From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med. Hypotheses72(3), 297–305 (2009).
   PubMed Web of Science ®Google Scholar
• White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int. Rev. Neurobiol.81, 85–110 (2007).
   PubMed Web of Science ®Google Scholar
• Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol. Ther.90(1), 21–34 (2001).
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Eser D, Zwanzger P, Moller HJ. GABAA receptors as targets for novel anxiolytic drugs. World J. Biol. Psychiatry7(4), 231–237 (2006).
   PubMed Web of Science ®Google Scholar
• Wieland HA, Luddens H, Seeburg PH. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J. Biol. Chem.267(3), 1426–1429 (1992).
   PubMed Web of Science ®Google Scholar
• Möhler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Therapeut.300(1), 2–8 (2002).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB. Anxiolytics: past, present, and future agents. J. Clin. Psychiatry64(Suppl. 3), 3–6 (2003).
   Google Scholar
• Griebel G, Perrault G, Simiand J et al. SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev.9(1), 3–20 (2003).
   PubMedGoogle Scholar
• Griebel G, Perrault G, Simiand J et al. SL651498: an anxioselective compound with functional selectivity for α2- and α3-containing γ-aminobutyric acid(A) (GABA(A)) receptors. J. Pharmacol. Exp.Ther.298(2), 753–768 (2001).
   PubMed Web of Science ®Google Scholar
• de Haas SL, Franson KL, Schmitt JAJ et al. The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A 2,3 selective agonist, in comparison with lorazepam in healthy volunteers. J. Psychopharmacol.23(6), 625–632 (2009).
   PubMed Web of Science ®Google Scholar
• Ashton H, Young A. GABA-ergic drugs: exit stage left, enter stage right. J. Psychopharmacol.17(2), 174–178 (2003).
   PubMed Web of Science ®Google Scholar
• Ashton H. The diagnosis and management of benzodiazepine dependence. Curr. Opin. Psychiatry18(249), 255 (2005).
   Google Scholar
• Nutt D, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch. Gen. Psychiatry47(10), 917–925 (1990).
   PubMed Web of Science ®Google Scholar
• Ballenger J. Overview of different pharmacotherapies for attaining remission in generalised anxiety disorder. J. Clin. Psychiatry62(Suppl 19), 11–19 (2001).
   PubMedGoogle Scholar
• Rocca P, Ferrero P, Gualerzi A et al. Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatr. Scand.84(6), 537–544 (1991).
   PubMedGoogle Scholar
• Ferrarese C, Appollonio I, Frigo M et al. Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr. Scand.82(2), 169–173 (1990).
   PubMed Web of Science ®Google Scholar
• Weizman R, Tanne Z, Granek M et al. Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur. J. Pharmacol.138(2), 289–292 (1987).
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br. J. Psychiatry179, 390–396 (2001).
   PubMed Web of Science ®Google Scholar
• Cameron OG, Huang GC, Nichols T et al. Reduced γ-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder. Arch. Gen. Psychiatry64(7), 793–800 (2007).
   PubMed Web of Science ®Google Scholar
• Hasler G, Nugent AC, Carlson PJ, Carson RE, Geraci M, Drevets WC. Altered cerebral γ-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch. Gen. Psychiatry65(10), 1166–1175 (2008).
   PubMed Web of Science ®Google Scholar
• Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch. Gen. Psychiatry55(8), 715–720 (1998).
   PubMed Web of Science ®Google Scholar
• Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents. J. Clin. Psychiatry66(Suppl. 2), 21–27 (2005).
   PubMed Web of Science ®Google Scholar
• Committee on the Safety of Medicines. Benzodiazepines, dependence and withdrawal symptoms. Curr. Probl.21, 1–2 (1988).
   Google Scholar
• Royal College of Psychiatrists. Benzodiazepines: Risks, Benefits Or Dependence. A Re-evaluation. Royal College of Psychiatrists, London, UK (1997).
   Google Scholar
• Sinclair LI, Christmas DM, Hood SD et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br. J. Psychiatry194(6), 483–490 (2009).
   PubMed Web of Science ®Google Scholar
• Baron C, Marcotte JE. Role of panic attacks in the intractability of asthma in children. Pediatrics94(1), 108–110 (1994).
   PubMedGoogle Scholar
• DeVane CL, Hill M, Antal EJ. Therapeutic drug monitoring of alprazolam in adolescents with asthma. Ther. Drug Monit.20(3), 257–260 (1998).
   Google Scholar
• Glue P, Fang A, Gandelman K, Klee B. Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. Am. J. Ther.13(5), 418–422 (2006).
   Google Scholar
• Simeon JG, Ferguson HB. Alprazolam effects in children with anxiety disorders. Can. J. Psychiatry32(7), 570–574 (1987).
   PubMed Web of Science ®Google Scholar
• Simeon JG, Ferguson HB, Knott V et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J. Am. Acad. Child Adolesc. Psychiatry31(1), 29–33 (1992).
   PubMed Web of Science ®Google Scholar
• Biederman J. Clonazepam in the treatment of prepubertal children with panic-like symptoms. J. Clin. Psychiatry48(Suppl.), 38–42 (1987).
   PubMed Web of Science ®Google Scholar
• Graae F. High anxiety in children. J. Clin. Psychiatry51(Suppl.), 18–19 (1990).
   Google Scholar
• Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood anxiety disorders. J. Am. Acad. Child Adolesc. Psychiatry33(3), 372–376 (1994).
   PubMed Web of Science ®Google Scholar
• Abu-Kishk I, Toledano M, Reis A, Daniel D, Berkovitch M. Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic. J. Toxicol. Clin. Toxicol.42(6), 921–925 (2004).
   PubMed Web of Science ®Google Scholar
• Barnett MS. Ziprasidone monotherapy in pediatric bipolar disorder. J. Child Adolesc. Psychopharmacol.14(3), 471–477 (2004).
   PubMed Web of Science ®Google Scholar
• Erermis S, Bildik T, Tamar M, Gockay A, Karasoy H, Ercan ES. Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl. Clin. Toxicol. (Phila)45(3), 277–280 (2007).
   PubMed Web of Science ®Google Scholar
• Kakooza-Mwesige A, Wachtel LE, Dhossche DM. Catatonia in autism: implications across the life span. Eur. Child Adolesc. Psychiatry17(6), 327–335 (2008).
   Google Scholar
• Khan SS, Mican LM. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents. J. Child Adolesc. Psychopharmacol.16(6), 671–677 (2006).
   PubMedGoogle Scholar
• McCall JE, Fischer CG, Warden G et al. Lorazepam given the night before surgery reduces preoperative anxiety in children undergoing reconstructive burn surgery. J. Burn Care Rehabil.20(2), 151–154 (1999).
   Google Scholar
• Phan H, Casavant MJ, Crockett S, Lee A, Hall MW, Nahata MC. Serotonin syndrome following a single 50 mg dose of sertraline in a child. Clin. Toxicol. (Phila.)46(9), 845–849 (2008).
   PubMed Web of Science ®Google Scholar
• Pruett JR, Rizvi ST. A 16-year-old girl with excited catatonia treated with low-dose oral lorazepam. J. Child Adolesc. Psychopharmacol.15(6), 1005–1010 (2005).
   Google Scholar
• Ratcliff SL, Brown A, Rosenberg L et al. The effectiveness of a pain and anxiety protocol to treat the acute pediatric burn patient. Burns32(5), 554–562 (2006).
   PubMedGoogle Scholar
• Schwartz TL, Nihalani N. Tiagabine in anxiety disorders. Expert Opin. Pharmacother.7(14), 1977–1987 (2006).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA. J. Clin. Psychiatry65(3), 291–292 (2004).
   PubMed Web of Science ®Google Scholar
• Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol. Psychiatry52(10), 1008–1030 (2002).
   PubMed Web of Science ®Google Scholar
• Pollack MH, Roy-Byrne PP, Van AM et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J. Clin. Psychiatry66(11), 1401–1408 (2005).
   PubMed Web of Science ®Google Scholar
• Zwanzger P, Eser D, Padberg F et al. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress. Anxiety18(3), 140–143 (2003).
   PubMedGoogle Scholar
• Pollack MHM, Tiller JF, Xie FP, Trivedi MHM. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J. Clin. Psychopharmacol.28(3), 308–316 (2008).
   PubMed Web of Science ®Google Scholar
• Schwartz TL. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol. Bull.36(2), 53–57 (2002).
   PubMedGoogle Scholar
• Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J. Clin. Psychiatry64(10), 1245–1249 (2003).
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berl.)184(1), 21–25 (2006).
   PubMed Web of Science ®Google Scholar
• Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. J. Clin. Psychiatry64(12), 1421–1425 (2003).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J. Clin. Psychopharmacol.27(1), 85–88 (2007).
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Sheehan KH, Raj BA, Janavs J. An open-label study of tiagabine in panic disorder. Psychopharmacol. Bull.40(3), 32–40 (2007).
   Google Scholar
• Zwanzger P, Baghai TC, Schule C et al. Tiagabine improves panic and agoraphobia in panic disorder patients. J. Clin. Psychiatry62(8), 656–657 (2001).
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT. Tiagabine for social anxiety disorder. Hum. Psychopharmacol.22(4), 241–244 (2007).
   PubMed Web of Science ®Google Scholar
• Bauer J, Cooper-Mahkorn D. Tiagabine: efficacy and safety in partial seizures – current status. Neuropsychiatr. Dis. Treat.4(4), 731–736 (2008).
   PubMedGoogle Scholar
• Sackellares JC, Krauss G, Sommerville KW, Deaton R. Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia43(4), 394–398 (2002).
   PubMed Web of Science ®Google Scholar
• Sayin U, Purali N, Ozkan T, Altug T, Buyukdevrim S. Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav.43(2), 529–535 (1992).
   Google Scholar
• Sherif F, Harro J, el-Hwuegi A, Oreland L. Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (γ-vinyl GABA) on rat exploratory activity. Pharmacol. Biochem. Behav.49(4), 801–805 (1994).
   PubMedGoogle Scholar
• Zwanzger P, Rupprecht R. Vigabatrin and tiagabine might have antipanic properties. J. Psychopharmacol.18(3), 440 (2004).
   Google Scholar
• Zwanzger P, Baghai TC, Schuele C et al. Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology25(5), 699–703 (2001).
   PubMed Web of Science ®Google Scholar
• Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J. Psychiatry Neurosci.30(3), 167–175 (2005).
   PubMed Web of Science ®Google Scholar
• Kalviainen R, Nousiainen I, Mantyjarvi M et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology53(5), 922 (1999).
   PubMed Web of Science ®Google Scholar
• de Wit H, Vicini L, Haig GM, Hunt T, Feltner D. Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J. Clin. Psychopharmacol.26(3), 268–273 (2006).
   PubMed Web of Science ®Google Scholar
• Hamner MB, Faldowski RA, Robert S, Ulmer HG, Horner MD, Lorberbaum JP. A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann. Clin. Psychiatry21(2), 89–94 (2009).
   PubMed Web of Science ®Google Scholar
• Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J. Clin. Psychopharmacol.28(1), 84–88 (2008).
   PubMed Web of Science ®Google Scholar
• Kinrys G, Pollack MH, Simon NM, Worthington JJ, Nardi AE, Versiani M. Valproic acid for the treatment of social anxiety disorder. Int. Clin. Psychopharmacol.18(3), 169–172 (2003).
   PubMed Web of Science ®Google Scholar
• Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J. Clin. Psychiatry55(4), 134–136 (1994).
   Google Scholar
• Keck PE Jr, Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol. Psychiatry33(7), 542–546 (1993).
   PubMedGoogle Scholar
• Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can. J. Psychiatry35(3), 248–250 (1990).
   PubMed Web of Science ®Google Scholar
• Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J. Psychiatry Neurosci.17(2), 78–80 (1992).
   Web of Science ®Google Scholar
• Roberts GM, Majoie HJ, Leenen LA et al. Ketter’s hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. Epilepsy Behav.6(3), 366–372 (2005).
   Google Scholar
• Romigi A, Cervellino A, Marciani MG et al. Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study. Eur. J. Neurol.15(2), 190–195 (2008).
   PubMed Web of Science ®Google Scholar
• Janowsky DS, Kraus JE, Barnhill J, Elamir B, Davis JM. Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective study. J. Clin. Psychopharmacol.23(5), 500–504 (2003).
   Google Scholar
• Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Clin. Neuropharmacol.26(4), 199–206 (2003).
   PubMed Web of Science ®Google Scholar
• Arbaizar B, Gomez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen. Hosp. Psychiatry30(5), 471–475 (2008).
   Google Scholar
• Berlant JL. Topiramate in posttraumatic stress disorder: preliminary clinical observations. J. Clin. Psychiatry62(Suppl. 17), 60–63 (2001).
   PubMed Web of Science ®Google Scholar
• Sempere AP, Medrano V, Berenguer-Ruiz L. Reversible dementia secondary to topiramate. Clin. Neuropharmacol.31(1), 62 (2008).
   Google Scholar
• Johnson BA, Rosenthal N, Capece JA et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA298(14), 1641–1651 (2007).
   PubMed Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mousavi G et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J. Psychopharmacol.23(2), 157–162 (2009).
   PubMed Web of Science ®Google Scholar
• Duggal HS, Singh I. Worsening of psychosis or topiramate-induced adverse event? Gen. Hosp. Psychiatry26(3), 245–247 (2004).
   Google Scholar
• Wheeler SD. Donepezil treatment of topiramate-related cognitive dysfunction. Headache46(2), 332–335 (2006).
   PubMed Web of Science ®Google Scholar
• Kober D, Gabbard GO. Topiramate-induced psychosis. Am. J. Psychiatry162(8), 1542 (2005).
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Tullidge A, Tidwell J, Sullivan KL, Hauser RA. Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. Clin. Neuropharmacol.29(3), 168–169 (2006).
   Google Scholar
• Damsa C, Warczyk S, Cailhol L et al. Panic attacks associated with topiramate. J. Clin. Psychiatry67(2), 326–327 (2006).
   Google Scholar
• Johnson BA, it-Daoud N, Bowden CL et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet361(9370), 1677–1685 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem. Pharmacol.75(1), 34–56 (2008).
   PubMed Web of Science ®Google Scholar
• Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC. Psychiatry4, 24 (2004).
   PubMed Web of Science ®Google Scholar
• Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J. Clin. Psychopharmacol.27(6), 677–681 (2007).
   PubMed Web of Science ®Google Scholar
• Tucker P, Trautman RP, Wyatt DB et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry68(2), 201–206 (2007).
   PubMed Web of Science ®Google Scholar
• Mello MF, Yeh MS, Barbosa NJ et al. A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder. BMC Psychiatry9, 28 (2009).
   PubMedGoogle Scholar
• Van AM, Mancini C, Patterson B, Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress. Anxiety23(1), 1–5 (2006).
   Google Scholar
• Rubio G, Jimenez-Arriero MA, Martinez-Gras I, Manzanares J, Palomo T. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder. J. Clin. Psychopharmacol.26(3), 341–344 (2006).
   PubMed Web of Science ®Google Scholar
• Malcolm RJ. GABA systems, benzodiazepines, and substance dependence. J. Clin. Psychiatry64(Suppl. 3), 36–40 (2003).
   PubMedGoogle Scholar
• Ntais C, Pakos E, Kyzas P, Ioannidis JP. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst. Rev. (3), CD005063 (2005).
   Google Scholar
• Paparrigopoulos T, Tzavellas E, Karaiskos D, Malitas P, Liappas I. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. J. Psychopharmacol. DOI: 10.1177/0269881109103799 (2009) (Epub ahead of print).
   Google Scholar
• Lingford-Hughes AR, Welch S, Nutt DJ. Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol.18(3), 293–335 (2004).
   PubMed Web of Science ®Google Scholar
• Florez G, Garcia-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin. Exp. Res.32(7), 1251–1259 (2008).
   PubMed Web of Science ®Google Scholar
• Brodie JD, Case BG, Figueroa E et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am. J. Psychiatry166(11), 1269–1277 (2009).
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati H, Lynch KG et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend.75(3), 233–240 (2004).
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, Garcia EF, Case G, DeMartinis N, Greenblatt D. Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl.)141(1), 1–5 (1999).
   PubMed Web of Science ®Google Scholar
• Cheseaux M, Monnat M, Zullino DF. Topiramate in benzodiazepine withdrawal. Hum. Psychopharmacol.18(5), 375–377 (2003).
   PubMed Web of Science ®Google Scholar
• Michopoulos I, Douzenis A, Christodoulou C, Lykouras L. Topiramate use in alprazolam addiction. World J. Biol. Psychiatry7(4), 265–267 (2006).
   PubMed Web of Science ®Google Scholar
• Zullino DF, Cottier AC, Besson J. Topiramate in opiate withdrawal. Prog. Neuropsychopharmacol. Biol. Psychiatry26(6), 1221–1223 (2002).
   PubMed Web of Science ®Google Scholar
• Pokk P, Vali M. The effects of flumazenil, Ro 154513 and β-CCM on the behaviour of control and stressed mice in the staircase test. J. Psychopharmacol.15(3), 155–159 (2001).
   Google Scholar
• Shelton KL, Grant KA. Effects of naltrexone and Ro 15-4513 on a multiple schedule of ethanol and tang self-administration. Alcohol Clin. Exp. Res.25(11), 1576–1585 (2001).
   Google Scholar
• Lingford-Hughes A, Hume SP, Feeney A et al. Imaging the GABA-benzodiazepine receptor subtype containing the α5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J. Cereb. Blood Flow Metab.22(7), 878–889 (2002).
   Google Scholar
• Lister RG, Karanian JW. RO 15–4513 induces seizures in DBA/2 mice undergoing alcohol withdrawal. Alcohol4(5), 409–411 (1987).
   PubMed Web of Science ®Google Scholar
• Lister RG, Nutt DJ. RO 15-4513 and its interaction with ethanol. Adv. Alcohol Subst. Abuse7(3–4), 119–123 (1988).
   PubMedGoogle Scholar
• Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin. Neuropharmacol.26(1), 1–4 (2003).
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Gonopolski Y, Musin E, Kotler M. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin. Neuropharmacol.28(1), 6–10 (2005).
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Musin E, Gonopolsky Y, Kotler M. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J. Clin. Psychopharmacol.27(6), 620–624 (2007).
   PubMed Web of Science ®Google Scholar
• Guzman CS, Filomensky T, Tavares H. Compulsive buying treatment with topiramate, a case report. Rev. Bras. Psiquiatr.29(4), 383–384 (2007).
   Google Scholar
• Shiah IS, Chao CY, Mao WC, Chuang YJ. Treatment of paraphilic sexual disorder: the use of topiramate in fetishism. Int. Clin. Psychopharmacol.21(4), 241–243 (2006).
   PubMed Web of Science ®Google Scholar
• Lochner C, Seedat S, Niehaus DJ, Stein DJ. Topiramate in the treatment of trichotillomania: an open-label pilot study. Int. Clin. Psychopharmacol.21(5), 255–259 (2006).
   PubMed Web of Science ®Google Scholar
• Emrich HM, von ZD, Kissling W, Moller HJ, Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch. Psychiatr. Nervenkr.229(1), 1–16 (1980).
   PubMedGoogle Scholar
• Berrettini WH, Nurnberger JI Jr, Hare TA, Simmons-Alling S, Gershon ES, Post RM. Reduced plasma and CSF γ-aminobutyric acid in affective illness: effect of lithium carbonate. Biol. Psychiatry18(2), 185–194 (1983).
   PubMedGoogle Scholar
• Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin. Ther. Targets9(1), 153–168 (2005).
   PubMed Web of Science ®Google Scholar
• Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC. A preliminary metabolomic analysis of older adults with and without depression. Int. J. Geriatr. Psychiatry22(5), 418–423 (2007).
   PubMed Web of Science ®Google Scholar
• Petty F, Sherman AD. Plasma GABA levels in psychiatric illness. J. Affect. Disord.6(2), 131–138 (1984).
   PubMed Web of Science ®Google Scholar
• Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am. J. Psychiatry159(4), 663–665 (2002).
   PubMed Web of Science ®Google Scholar
• Sanacora G, Mason GF, Rothman DL et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am. J. Psychiatry160(3), 577–579 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor M, Bhagwagar Z, Cowen PJ, Sharp T. GABA and mood disorders. Psychol. Med.33(3), 387–393 (2003).
   Google Scholar
• Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol. Psychiatry38(9), 578–591 (1995).
   PubMed Web of Science ®Google Scholar
• Hall RC, Zisook S. Paradoxical reactions to benzodiazepines. Br. J. Clin. Pharmacol.11(Suppl. 1), 99S–104S (1981).
   PubMed Web of Science ®Google Scholar
• Macritchie K, Geddes JR, Scott J, Haslam D, de LM, Goodwin G. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst. Rev. (1), CD004052 (2003).
   Google Scholar
• Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst. Rev.3, CD003196 (2001).
   Google Scholar
• Beynon S, Soares-Weiser K, Woolacott N, Duffy S, Geddes JR. Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials. J. Psychopharmacol.23(5), 574–591 (2009).
   PubMedGoogle Scholar
• Bhangoo RK, Lowe CH, Myers FS et al. Medication use in children and adolescents treated in the community for bipolar disorder. J. Child Adolesc. Psychopharmacol.13(4), 515–522 (2003).
   PubMed Web of Science ®Google Scholar
• Consoli A, Brunelle J, Bodeau N et al. Medication use in adolescents treated in a French psychiatric setting for acute manic or mixed episode. J. Can. Acad. Child Adolesc. Psychiatry18(3), 231–238 (2009).
   Google Scholar
• Wagner KD, Redden L, Kowatch RA et al. A double-blind, randomized, placebo-controlled trial of divalproex extended-release in the treatment of bipolar disorder in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry48(5), 519–532 (2009).
   PubMed Web of Science ®Google Scholar
• McVearry KM, Gaillard WD, VanMeter J, Meador KJ. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav.16(4), 609–616 (2009).
   PubMed Web of Science ®Google Scholar
• Chouinard G. The use of benzodiazepines in the treatment of manic-depressive illness. J. Clin. Psychiatry49(Suppl.), 15–20 (1988).
   PubMed Web of Science ®Google Scholar
• Bradwejn J, Shriqui C, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J. Clin. Psychopharmacol.10(6), 403–408 (1990).
   PubMed Web of Science ®Google Scholar
• Ketter TA, Wang PW. The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disorders. J. Clin. Psychiatry64(Suppl. 3), 15–20 (2003).
   PubMed Web of Science ®Google Scholar
• Ring HA, Crellin R, Kirker S, Reynolds EH. Vigabatrin and depression. J. Neurol. Neurosurg. Psychiatry56(8), 925–928 (1993).
   PubMed Web of Science ®Google Scholar
• Williams J, Ranney L, Morgan LC, Whitener L. How reviews covered the unfolding scientific story of gabapentin for bipolar disorder. Gen. Hosp. Psychiatry31(3), 279–287 (2005).
   Google Scholar
• Hamrin V, Bailey K. Gabapentin and methylphenidate treatment of a preadolescent with attention deficit hyperactivity disorder and bipolar disorder. J. Child Adolesc. Psychopharmacol.11(3), 301–309 (2001).
   PubMed Web of Science ®Google Scholar
• Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA. Gabapentin augmentation therapy in bipolar depression. Bipolar. Disord.4(5), 296–301 (2002).
   PubMed Web of Science ®Google Scholar
• Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord.8(1), 15–27 (2006).
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, McElroy SL, Shelton MD. A pilot study of topiramate as monotherapy in the treatment of acute mania. J. Clin. Psychopharmacol.21(3), 340–342 (2001).
   PubMed Web of Science ®Google Scholar
• Roy Chengappa K, Schwarzman L, Hulihan J, Xiang J, Rosenthal N, Clinical Affairs Product Support Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: a randomized, placebo-controlled trial. J. Clin. Psychiatry67, 1698–1706 (2006).
   PubMed Web of Science ®Google Scholar
• Bahk WM, Shin YC, Woo JM et al. Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. Prog. Neuropsychopharmacol. Biol. Psychiatry29(1), 115–121 (2005).
   Google Scholar
• Lykouras L, Hatzimanolis J. Adjunctive topiramate in the maintenance treatment of bipolar disorders: an open-label study. Curr. Med. Res. Opin.20(6), 843–847 (2004).
   PubMed Web of Science ®Google Scholar
• Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J. Affect. Disord.50(2–3), 245–251 (1998).
   PubMed Web of Science ®Google Scholar
• Normann C, Langosch J, Schaerer LO, Grunze H, Walden J. Treatment of acute mania with topiramate. Am. J. Psychiatry156(12), 2014 (1999).
   PubMed Web of Science ®Google Scholar
• Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am. J. Psychiatry156(6), 968–969 (1999).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Riccardelli R, Binder C, Kusumakar V. Open-label adjunctive topiramate in the treatment of unstable bipolar disorder. Can. J. Psychiatry50(7), 415–422 (2005).
   Google Scholar
• McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord.4(3), 207–213 (2002).
   PubMed Web of Science ®Google Scholar
• Klufas A, Thompson D. Topiramate-induced depression. Am. J. Psychiatry158(10), 1736 (2001).
   PubMed Web of Science ®Google Scholar
• Tamada RS, Amaral JA, Issler CK, Lafer B. Treatment emergent affective switch with topiramate. Rev. Bras. Psiquiatr.28(2), 158 (2006).
   Google Scholar
• Barzman DH, Delbello MP, Kowatch RA et al. Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders. J. Child Adolesc. Psychopharmacol.15(6), 931–937 (2005).
   PubMed Web of Science ®Google Scholar
• Delbello MP, Findling RL, Kushner S et al. A pilot controlled trial of topiramate for mania in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry44(6), 539–547 (2005).
   PubMed Web of Science ®Google Scholar
• Nickel C, Lahmann C, Tritt K et al. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J. Affective Disord.87(2–3), 243–252 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt do Prado-Lima PA, Bacaltchuck J. Topiramate in treatment-resistant depression and binge-eating disorder. Bipolar Disord.4(4), 271–273 (2002).
   Google Scholar
• Carpenter LL, Schecter JM, Tyrka AR et al. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J. Clin. Psychiatry67(1), 66–71 (2006).
   PubMed Web of Science ®Google Scholar
• Young AH, Geddes JR, Macritchie K, Rao SN, Vasudev A. Tiagabine in the maintenance treatment of bipolar disorders. Cochrane Database Syst. Rev.3, CD005173 (2006).
   Google Scholar
• Young AH, Geddes JR, Macritchie K, Rao SN, Watson S, Vasudev A. Tiagabine in the treatment of acute affective episodes in bipolar disorder: efficacy and acceptability. Cochrane Database Syst. Rev.3, CD004694 (2006).
   Google Scholar
• Brown GM, Stone GH, Rathbone MP. Primidone and rapid cycling affective disorders. Lancet342(8876), 925 (1993).
   Google Scholar
• Schaffer LC, Schaffer CB, Caretto J. The use of primidone in the treatment of refractory bipolar disorder. Ann. Clin. Psychiatry11(2), 61–66 (1999).
   Google Scholar
• Ebert B, Wafford K, Deacon S. Treating insomnia: current and investigational pharmacological approaches. Pharmacol. Therapeut.112, 612–629 (2006).
   PubMed Web of Science ®Google Scholar
• Armour A, Gottschlich MM, Khoury J, Warden GD, Kagan RJ. A randomized, controlled prospective trial of zolpidem and haloperidol for use as sleeping agents in pediatric burn patients. J. Burn Care Res.29(1), 238–247 (2008).
   Google Scholar
• Blumer JL, Reed MD, Steinberg F et al. Potential pharmacokinetic basis for zolpidem dosing in children with sleep difficulties. Clin. Pharmacol. Ther.83(4), 551–558 (2008).
   Google Scholar
• Blumer JL, Findling RL, Shih WJ, Soubrane C, Reed MD. Controlled clinical trial of zolpidem for the treatment of insomnia associated with attention-deficit/hyperactivity disorder in children 6 to 17 years of age. Pediatrics123(5), e770–e776 (2009).
   PubMed Web of Science ®Google Scholar
• Mancini J, Thirion X, Masut A et al. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol. Drug Saf.15(7), 494–503 (2006).
   PubMed Web of Science ®Google Scholar
• Saul S. Merck cancels work on a new insomnia medication. The New York Times. NY, USA, 27 March (2007).
   Google Scholar
• Walsh JK, Perlis M, Rosenthal M, Krystal A, Jiang J, Roth T. Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia. J. Clin. Sleep Med.2(1), 35–41 (2006).
   PubMed Web of Science ®Google Scholar
• Roth T, Wright KP Jr, Walsh J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study. Sleep29(3), 335–341 (2006).
   PubMed Web of Science ®Google Scholar
• Walsh JK, Zammit G, Schweitzer PK, Ondrasik J, Roth T. Tiagabine enhances slow wave sleep and sleep maintenance in primary insomnia. Sleep Med.7(2), 155–161 (2006).
   Google Scholar
• Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can. J. Psychiatry49(7), 439–453 (2004).
   PubMed Web of Science ®Google Scholar
• Schmitt HP. Pouring oil into the fire? On the conundrum of the beneficial effects of NMDA receptor antagonists in Alzheimer disease. Psychopharmacology (Berl.)179(1), 151–153 (2005).
   Google Scholar
• Mohr E, Bruno G, Foster N et al. GABA-agonist therapy for Alzheimer’s disease. Clin. Neuropharmacol.9(3), 257–263 (1986).
   Google Scholar
• Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can. J. Psychiatry49(7), 439–453 (2004).
   PubMed Web of Science ®Google Scholar
• Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can. J. Psychiatry49(7), 439–453 (2004).
   PubMed Web of Science ®Google Scholar
• Amann B, Pantel J, Grunze H et al. Anticonvulsants in the treatment of aggression in the demented elderly: an update. Clin. Pract. Epidemol. Ment. Health5, 14 (2009).
   Google Scholar
• Lonergan E, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst. Rev.3, CD003945 (2009).
   Google Scholar
• Fhager B, Meiri IM, Sjogren M, Edman A. Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study. Int. Psychogeriatr.15(3), 307–309 (2003).
   PubMed Web of Science ®Google Scholar
• Shannon HE, Love PL. Effects of antiepileptic drugs on working memory as assessed by spatial alternation performance in rats. Epilepsy Behav.5(6), 857–865 (2004).
   Google Scholar
• Shannon HE, Love PL. Effects of antiepileptic drugs on attention as assessed by a five-choice serial reaction time task in rats. Epilepsy Behav.7(4), 620–628 (2005).
   Google Scholar
• Collinson N, Kuenzi FM, Jarolimek W et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α 5 subunit of the GABAA receptor. J. Neurosci.22(13), 5572–5580 (2002).
   PubMed Web of Science ®Google Scholar
• Atack JR. GABA(A) receptor subtype-selective efficacy: TPA023, an α2/α3 selective non-sedating anxiolytic and α5IA, an α5 selective cognition enhancer. CNS Neurosci. Ther.14(1), 25–35 (2008).
   PubMed Web of Science ®Google Scholar
• Dawson GR, Maubach KA, Collinson N et al. An inverse agonist selective for a5 subunit-containing GABAA receptors enhances cognition. J. Pharmacol. Exp.Ther.316(3), 1335–1345 (2006).
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Besson M, Wilson SJ, Dawson GR, Lingford-Hughes AR. Blockade of alcohol’s amnestic activity in humans by an a5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology53(7), 810–820 (2007).
   PubMed Web of Science ®Google Scholar
• Buettelmann B, Ballard TM, Gasser R et al. Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA a5 inverse agonists with potential for the treatment of cognitive dysfunction. Bioorg. Med. Chem. Lett.19(20), 5958–5961 (2009).
   Google Scholar
• Knust H, Achermann G, Ballard T et al. The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA α5 inverse agonists for the treatment of cognitive dysfunction. Bioorg. Med. Chem. Lett.19(20), 5940–5944 (2009).
   PubMed Web of Science ®Google Scholar
• Roberts E. Prospects for research on schizophrenia. An hypotheses suggesting that there is a defect in the GABA system in schizophrenia. Neurosci. Res. Program. Bull.10(4), 468–482 (1972).
   PubMedGoogle Scholar
• Wassef AAM, Dott SGM, Harris AR et al. Critical review of GABA-ergic drugs in the treatment of schizophrenia. J. Clin. Psychopharmacol.19(3), 222–232 (1999).
   PubMedGoogle Scholar
• Wassef A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science and clinical studies. J. Clin. Psychopharmacol.23(6), 601–640 (2003).
   PubMed Web of Science ®Google Scholar
• Costa E, Grayson DR, Mitchell CP, Tremolizzo L, Veldic M, Guidotti A. GABAergic cortical neuron chromatin as a putative target to treat schizophrenia vulnerability. Crit. Rev. Neurobiol.15(2), 121–142 (2003).
   PubMedGoogle Scholar
• Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol.24(1), 43–49 (2001).
   PubMed Web of Science ®Google Scholar
• van Kammen DP, Guidotti A, Kelley ME et al. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships. Biol. Psychiatry34(8), 515–522 (1993).
   PubMedGoogle Scholar
• van Kammen DP. γ-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia. Am. J. Psychiatry134(2), 138–143 (1977).
   PubMed Web of Science ®Google Scholar
• Guidotti A, Auta J, Davis JM et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl.)180(2), 191–205 (2005).
   PubMed Web of Science ®Google Scholar
• Wobrock T, Schneider M, Kadovic D et al. Reduced cortical inhibition in first-episode schizophrenia. Schizophr. Res.105(1–3), 252–261 (2008).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat. Med.12(9), 1016–1022 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis DA, Volk DW, Hashimoto T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl.)174(1), 143–150 (2004).
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am. J. Psychiatry148(6), 714–726 (1991).
   PubMed Web of Science ®Google Scholar
• Lara DR. Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit. Cell. Mol. Neurobiol.22(3), 239–247 (2002).
   Google Scholar
• De Fruyt J, Demyttenaere K. Rapid tranquilization: new approaches in the emergency treatment of behavioral disturbances. Eur. Psychiatry19(5), 243–249 (2004).
   PubMed Web of Science ®Google Scholar
• Pilowsky LS, Ring H, Shine PJ, Battersby M, Lader M. Rapid tranquillisation. A survey of emergency prescribing in a general psychiatric hospital. Br. J. Psychiatry160(6), 831–835 (1992).
   PubMed Web of Science ®Google Scholar
• Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int. Clin. Psychopharmacol.12(3), 175–179 (1997).
   PubMed Web of Science ®Google Scholar
• Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can. J. Psychiatry38(Suppl. 4), S114–S121 (1993).
   PubMedGoogle Scholar
• Guz I, Moraes R, Sartoretto JN. The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: a double-blind study. Curr. Ther. Res. Clin. Exp.14(12), 767–774 (1972).
   PubMed Web of Science ®Google Scholar
• Wyant M, Diamond BI, O’Neal E, Sloan A, Borison RL. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacol. Bull.26(1), 126–129 (1990).
   PubMedGoogle Scholar
• Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J. Psychiatr. Pract.11(Suppl. 1), 5–108 (2005).
   PubMedGoogle Scholar
• Bartholini G. [Potential therapeutic activity of GABA-mimetic drugs in neuropsychiatry]. Schweiz. Arch. Neurol. Neurochir. Psychiatr.125(2), 265–269 (1979).
   Google Scholar
• Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst. Rev. (3), CD004028 (2008).
   Google Scholar
• Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin. Neuropharmacol.28(4), 169–175 (2005).
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Halonen P, Wahlbeck K et al. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. J. Clin. Psychiatry66(8), 1012–1015 (2005).
   PubMed Web of Science ®Google Scholar
• Gobbi G, Gaudreau PO, Leblanc N. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. J. Clin. Psychopharmacol.26(5), 467–473 (2006).
   PubMed Web of Science ®Google Scholar
• Migliardi G, D’Arrigo C, Santoro V et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin. Neuropharmacol.30(2), 107–113 (2007).
   PubMed Web of Science ®Google Scholar
• McDaniel WW, Spiegel DR, Sahota AK. Topiramate effect in catatonia: a case series. J. Neuropsychiatry Clin. Neurosci.18(2), 234–238 (2006).
   PubMed Web of Science ®Google Scholar
• Sachdev PS. The current status of tardive dyskinesia. Aust. NZ J. Psychiatry34(3), 355–369 (2000).
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Crayton JW, Chase TN. Improvement in tardive dyskinesia after muscimol therapy. Arch. Gen. Psychiatry36(5), 595–598 (1979).
   PubMed Web of Science ®Google Scholar
• Cassady SL, Thaker GK, Moran M, Birt A, Tamminga CA. GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia. Biol. Psychiatry32(4), 302–311 (1992).
   Google Scholar
• Korsgaard S, Casey DE, Gerlach J. Effect of γ-vinyl GABA in tardive dyskinesia. Psychiatry Res8(4), 261–269 (1983).
   Google Scholar
• Lambert PA, Cantiniaux P, Chabannes JP, Tell GP, Schechter PJ, Koch-Weser J. [Therapeutic trial of γ-vinyl GABA, an inhibitor of GABA transaminase, in tardive dyskinesias induced by neuroleptics]. Encephale8(3), 371–376 (1982).
   Google Scholar
• Tamminga CA, Thaker GK, Ferraro TN, Hare TA. GABA agonist treatment improves tardive dyskinesia. Lancet2(8341), 97–98 (1983).
   Google Scholar
• Sander JW, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J. Neurol. Neurosurg. Psychiatry54(5), 435–439 (1991).
   PubMed Web of Science ®Google Scholar
• Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev.3, CD000205 (2006).
   Google Scholar
• Soares K, Rathbone J, Deeks J. G-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst. Rev. (4), CD000203 (2004).
   Google Scholar
• Aarsen FK, van den Akker EL, Drop SL, Catsman-Berrevoets CE. Effect of topiramate on cognition in obese children. Neurology67(7), 1307–1308 (2006).
   Google Scholar
• Nickel MK. Topiramate treatment of aggression in male borderline patients. Aust. NZ J. Psychiatry41(5), 461–462 (2007).
   PubMed Web of Science ®Google Scholar
• Loew TH, Nickel MK. Topiramate treatment of women with borderline personality disorder, part II: an open 18-month follow-up. J. Clin. Psychopharmacol.28(3), 355–357 (2008).
   PubMed Web of Science ®Google Scholar
• Cassano P, Lattanzi L, Pini S, Dell’Osso L, Battistini G, Cassano GB. Topiramate for self-mutilation in a patient with borderline personality disorder. Bipolar Disord.3(3), 161 (2001).
   Google Scholar
• Eccleston D, Cole AJ. Calcium-channel blockade and depressive illness. Br. J. Psychiatry156, 889–891 (1990).
   Google Scholar
• Lyndon RW, Johnson G, McKeough G. Nifedipine-induced depression. Br. J. Psychiatry159, 447–448 (1991).
   Google Scholar
• Hullett FJ, Potkin SG, Levy AB, Ciasca R. Depression associated with nifedipine-induced calcium channel blockade. Am. J. Psychiatry145(10), 1277–1279 (1988).
   PubMed Web of Science ®Google Scholar
• McAllister-Williams RH. Calcium-channel blockade and depressive illness. Br. J. Psychiatry157, 618–619 (1990).
   Google Scholar
• Hollister L, Garzia-Trevino E. Calcium channel blockers in psychiatric disorders: a review of the literature. Can. J. Psychiatry44, 658–664 (1999).
   PubMed Web of Science ®Google Scholar
• Wisner KL, Peindl KS, Perel JM, Hanusa BH, Piontek CM, Baab S. Verapamil treatment for women with bipolar disorder. Biol. Psychiatry51(9), 745–752 (2002).
   PubMed Web of Science ®Google Scholar
• Pae CU. Pregabalin augmentation to antidepressants in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry33(3), 577–578 (2009).
   PubMed Web of Science ®Google Scholar
• Mallinger AG, Thase ME, Haskett R et al. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord.10(8), 856–866 (2008).
   PubMed Web of Science ®Google Scholar
• Gitlin MJ, Weiss J. Verapamil as maintenance treatment in bipolar illness: a case report. J. Clin. Psychopharmacol.4(6), 341–343 (1984).
   PubMed Web of Science ®Google Scholar
• Kastner T, Friedman DL. Verapamil and valproic acid treatment of prolonged mania. J. Am. Acad. Child Adolesc. Psychiatry31(2), 271–275 (1992).
   PubMed Web of Science ®Google Scholar
• Levy NA, Janicak PG. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord.2(2), 108–119 (2000).
   PubMed Web of Science ®Google Scholar
• Manna V. [Bipolar affective disorders and role of intraneuronal calcium. Therapeutic effects of the treatment with lithium salts and/or calcium antagonist in patients with rapid polar inversion]. Minerva Med.82(11), 757–763 (1991).
   PubMedGoogle Scholar
• Oulis P, Florakis AA, Tzanoulinos G, Papadimitriou GN. Adjunctive pregabalin to quetiapine in acute mania. Clin. Neuropharmacol.32(3), 174 (2009).
   PubMed Web of Science ®Google Scholar
• Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int. Clin. Psychopharmacol.23(1), 18–28 (2008).
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin. Pharmacother.7(15), 2139–2154 (2006).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev. Neurother.7(7), 769–781 (2007).
   PubMedGoogle Scholar
• Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry40(4), 163–168 (2007).
   PubMed Web of Science ®Google Scholar
• Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br. J. Psychiatry193(5), 389–394 (2008).
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am. J. Psychiatry160(3), 533–540 (2003).
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch. Gen. Psychiatry62(9), 1022–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Kavoussi R. Pregabalin: From molecule to medicine. Eur. Neuropsychopharmacol.16(Suppl. 2), S128–S133 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin. Pharmacother.7(15), 2139–2154 (2006).
   PubMed Web of Science ®Google Scholar
• Pae CU, Marks DM, Han C, Masand PS, Patkar AA. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open label pilot study. Int. Clin. Psychopharmacol.24(1), 29–33 (2009).
   PubMed Web of Science ®Google Scholar
• Hidalgo RB, Tupler LA, Davidson JR. An effect–size analysis of pharmacologic treatments for generalized anxiety disorder. J. Psychopharmacol.21(8), 864–872 (2007).
   PubMed Web of Science ®Google Scholar
• Harnack D, Scheel M, Mundt A, Kupsch A, Heinz A, Strohle A. Pregabalin in patients with antidepressant treatment-resistant somatoform disorders: a case series. J. Clin. Psychopharmacol.27(5), 537–539 (2007).
   PubMed Web of Science ®Google Scholar
• Strawn JR, Dowling BP, Geracioti TD Jr. Pregabalin treatment of posttraumatic stress disorder. J. Clin. Psychopharmacol.28(5), 596–597 (2008).
   Google Scholar
• Oulis P, Masdrakis VG, Karapoulios E et al. Pregabalin augmentation to sertraline-risperidone combination in the treatment of obsessive-compulsive disorder. Prim. Care Companion J. Clin. Psychiatry10(3), 249- (2008).
   Google Scholar
• Montgomery A, Herman B, Schweizer E, Mandel F. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int. Clin. Psychopharmacol.24, 214–222 (2009).
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep28, 187–193 (2005).
   PubMed Web of Science ®Google Scholar
• Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO. Dimebon and tacrine inhibit neurotoxic action of β-amyloid in culture and block L-type Ca(2+) channels. Bull. Exp. Biol. Med132(5), 1079–1083 (2001).
   PubMed Web of Science ®Google Scholar
• Bachurin S, Bukatina E, Lermontova N et al. Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer. Ann. NY Acad. Sci.939, 425–435 (2001).
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet372(9634), 207–215 (2008).
   PubMed Web of Science ®Google Scholar
• Choudhary M, Nawaz S, ul-Haq Z et al. Juliflorine: a potent natural peripheral anionic-site-binding inhibitor of acetylcholinesterase with calcium-channel blocking potential, a leading candidate for Alzheimers disease therapy. Biochem. Biophys. Res. Comm.332, 1171–1179 (2005).
   PubMed Web of Science ®Google Scholar
• Marco-Contelles J, Leon R, de los RC et al. Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer’s disease. J. Med. Chem.49(26), 7607–7610 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev. (3), CD000147 (2002).
   Google Scholar
• Maxwell CJ, Hogan DB, Ebly EM. Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging. CMAJ161(5), 501–506 (1999).
   PubMed Web of Science ®Google Scholar
• Jimenez-Lerma JM, Landabaso M, Iraurgi L, Calle R, Sanz J, Gutierrez-Fraile M. Nimodipine in opiate detoxification: a controlled trial. Addiction97(7), 819–824 (2002).
   Google Scholar
• Altamura AC, Regazzetti MG, Porta M. Nimodipine in human alcohol withdrawal syndrome – an open study. Eur. Neuropsychopharmacol.1(1), 37–40 (1990).
   Google Scholar
• Little HJ, Dolin SJ, Halsey MJ. Calcium channel antagonists decrease the ethanol withdrawal syndrome. Life Sci.39(22), 2059–2065 (1986).
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di NM, Tedeschi D, Mazza M, Janiri L, Bria P. Efficacy and safety of pregabalin in alcohol dependence. Adv. Ther.25(6), 608–618 (2008).
   PubMed Web of Science ®Google Scholar
• Newton PM, Messing RO. The N-type calcium channel is a novel target for treating alcohol use disorders. Channels (Austin.)3(2), 77–81 (2009).
   PubMed Web of Science ®Google Scholar
• Newton PM, Zeng L, Wang V et al. A blocker of N- and T-type voltage-gated calcium channels attenuates ethanol-induced intoxication, place preference, self-administration, and reinstatement. J. Neurosci.28(45), 11712–11719 (2008).
   Google Scholar
• Shapira B, Nemets B, Trachtenberg A, Belmaker RH. Phenytoin as an augmentation for SSRI failures: a small controlled study. J. Affect. Disord.96(1–2), 123–126 (2006).
   PubMed Web of Science ®Google Scholar
• Nemets B, Bersudsky Y, Belmaker RH. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. J. Clin. Psychiatry66(5), 586–590 (2005).
   PubMed Web of Science ®Google Scholar
• Kalinowsky L, Putnam T. Attempts at treatment of schizophrenia and other non-epileptic psychoses with Dilantin. Arch. Neurological Psychiatry49, 414–420 (1943).
   Google Scholar
• Post RM, Berrettini W, Uhde TW, Kellner C. Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study. J. Clin. Psychopharmacol.4(4), 178–185 (1984).
   PubMed Web of Science ®Google Scholar
• Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: a controlled study. Am. J. Psychiatry157(3), 463–465 (2000).
   PubMed Web of Science ®Google Scholar
• Mishory A, Winokur M, Bersudsky Y. Prophylactic effect of phenytoin in bipolar disorder: a controlled study. Bipolar Disord.5(6), 464–467 (2003).
   Google Scholar
• Berk M. Lamotrigine and the treatment of mania in bipolar disorder. Eur. Neuropsychopharmacol.9(Suppl. 4), S119–S123 (1999).
   PubMed Web of Science ®Google Scholar
• Weisler RH, Calabrese JR, Bowden CL, Ascher JA, Veaugh-Geiss J, Evoniuk G. Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. J. Affect. Disord.108(1–2), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br. J. Psychiatry194(1), 4–9 (2009).
   PubMed Web of Science ®Google Scholar
• Pavuluri MN, Henry DB, Moss M, Mohammed T, Carbray JA, Sweeney JA. Effectiveness of lamotrigine in maintaining symptom control in pediatric bipolar disorder. J. Child Adolesc. Psychopharmacol.19(1), 75–82 (2009).
   PubMed Web of Science ®Google Scholar
• Chang K, Saxena K, Howe M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J. Am. Acad. Child Adolesc. Psychiatry45(3), 298–304 (2006).
   PubMed Web of Science ®Google Scholar
• Elphick M. The clinical uses and pharmacology of carbamazepine in psychiatry. Int. Clin. Psychopharmacol.3(3), 185–203 (1988).
   PubMed Web of Science ®Google Scholar
• Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harv. Rev. Psychiatry17(4), 231–241 (2009).
   PubMed Web of Science ®Google Scholar
• Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS. Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum. Psychopharmacol.24(1), 19–28 (2009).
   PubMed Web of Science ®Google Scholar
• Baethge C, Baldessarini RJ, Mathiske-Schmidt K et al. Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. J. Clin. Psychiatry66(2), 174–182 (2005).
   PubMedGoogle Scholar
• Stuppaeck CH, Barnas C, Schwitzer J, Fleischhacker WW. Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. J. Clin. Psychiatry55(4), 146–150 (1994).
   PubMed Web of Science ®Google Scholar
• Cullen M, Mitchell P, Brodaty H et al. Carbamazepine for treatment-resistant melancholia. J. Clin. Psychiatry52(11), 472–476 (1991).
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology40(3), 134–139 (1999).
   PubMed Web of Science ®Google Scholar
• Varney NR, Garvey MJ, Cook BL, Campbell DA, Roberts RJ. Identification of treatment-resistant depressives who respond favorably to carbamazepine. Ann. Clin. Psychiatry5(2), 117–122 (1993).
   Google Scholar
• Ciusani E, Zullino DF, Eap CB, Brawand-Amey M, Brocard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J. Psychopharmacol.18(4), 559–566 (2004).
   PubMed Web of Science ®Google Scholar
• Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, Sugawara K. Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int. Clin. Psychopharmacol.11(1), 55–57 (1996).
   Google Scholar
• Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur. Neuropsychopharmacol.12(3), 255–260 (2002).
   PubMed Web of Science ®Google Scholar
• Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine, IN, USA (2009).
   Google Scholar
• Joshi G, Wozniak J, Mick E et al. A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. J. Child Adolesc. Psychopharmacol.20(1), 7–14 (2010).
   PubMed Web of Science ®Google Scholar
• Dineen WK. Bipolar disorder and comorbid anxiety disorders in children and adolescents. J. Clin. Psychiatry67(Suppl. 1), 16–20 (2006).
   Google Scholar
• MacMillan CM, Korndorfer SR, Rao S, Fleisher CA, Mezzacappa E, Gonzalez-Heydrich J. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J. Psychiatr. Pract.12(4), 214–222 (2006).
   PubMedGoogle Scholar
• Premkumar TS, Pick J. Lamotrigine for schizophrenia. Cochrane Database Syst. Rev. (4), CD005962 (2006).
   Google Scholar
• Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res.109(1–3), 10–14 (2009).
   PubMed Web of Science ®Google Scholar
• Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ160(5), 649–655 (1999).
   PubMed Web of Science ®Google Scholar
• Polycarpou A, Papanikolaou P, Ioannidis JP, Contopoulos-Ioannidis DG. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst. Rev. (3), CD005064 (2005).
   Google Scholar
• Alldredge BK, Lowenstein DH, Simon RP. Placebo-controlled trial of intravenous diphenylhydantoin for short-term treatment of alcohol withdrawal seizures. Am. J. Med.87(6), 645–648 (1989).
   PubMed Web of Science ®Google Scholar
• Gessner PK. Is diphenylhydantoin effective in treatment of alcohol withdrawal? JAMA219(8), 1072 (1972).
   Google Scholar
• Sofuoglu M, Pentel PR, Bliss RL, Goldman AI, Hatsukami DK. Effects of phenytoin on cocaine self-administration in humans. Drug Alcohol Depend.53(3), 273–275 (1999).
   Google Scholar
• Crosby RD, Pearson VL, Eller C, Winegarden T, Graves NL. Phenytoin in the treatment of cocaine abuse: a double-blind study. Clin. Pharmacol. Ther.59(4), 458–468 (1996).
   Google Scholar
• Minozzi S, Amato L, Davoli M et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst. Rev. (2), CD006754 (2008).
   Google Scholar
• Klein E, Uhde TW, Post RM. Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal. Am. J. Psychiatry143(2), 235–236 (1986).
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Sullivan MD, Cowley DS, Ries RK. Adjunctive treatment of benzodiazepine discontinuation syndromes: a review. J. Psychiatr. Res.27(Suppl. 1), 143–153 (1993).
   Google Scholar
• Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch. Gen. Psychiatry48(5), 448–452 (1991).
   PubMed Web of Science ®Google Scholar
• Lanctot KL, Herrmann N, Mazzotta P, Khan LR, Ingber N. GABAergic function in Alzheimer’s disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can. J. Psychiatry49(7), 439–453 (2004).
   PubMed Web of Science ®Google Scholar
• Flint AJ, van RR. The pharmacologic treatment of Alzheimer’s disease: a guide for the general psychiatrist. Can. J. Psychiatry43(7), 689–697 (1998).
   PubMed Web of Science ®Google Scholar
• Ng B, Camacho A, Bardwell W, Sewell DD. Lamotrigine for agitation in older patients with dementia. Int. Psychogeriatrics21(1), 207–208 (2009).
   Google Scholar
• Devarajan S, Dursun SM. Aggression in dementia with lamotrigine treatment. Am. J. Psychiatry157(7), 1178 (2000).
   Google Scholar
• Nair V, Mahadevan S. Randomised controlled study-efficacy of clonidine versus carbamazepine in children with ADHD. J. Trop. Pediatr.55(2), 116–121 (2009).
   Google Scholar
• Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M. Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry35(4), 480–490 (1996).
   PubMed Web of Science ®Google Scholar
• Gerardin P, Cohen D, Mazet P, Flament MF. Drug treatment of conduct disorder in young people. Eur. Neuropsychopharmacol.12(5), 361–370 (2002).
   PubMed Web of Science ®Google Scholar
• Davids E, Kis B, Specka M, Gastpar M. A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry30(6), 1033–1038 (2006).
   PubMed Web of Science ®Google Scholar
• Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure–function relationships of voltage-gated calcium channels. Pharmacol. Rev.57(4), 411–425 (2005).
   PubMed Web of Science ®Google Scholar
• Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu. Rev. Cell Dev. Biol.16, 521–555 (2000).
   PubMed Web of Science ®Google Scholar